Dipexium Pharmaceuti (DPRX) 12.57 $DPRX
Dipexium Pharmaceuticals (DPRX) in Focus: Stock Gains 8.5%
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 7:45AM CDT
Dipexium Pharmaceuticals, Inc. (DPRX) was a big mover last session, as the company saw its shares rise over 8% on the day.
BSTC: 37.35 (+0.76), DPRX: 12.57 (-0.13)
Dipexium Pharmaceuticals Announces Participation in September Investor Conferences
PR Newswire - Wed Aug 24, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today announced plans to participate in two September investor conferences:
DPRX: 12.57 (-0.13)
Dipexium Pharmaceuticals Reports Second Quarter 2016 Financial Results
PR Newswire - Thu Aug 04, 6:00AM CDT
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today reported financial results for the quarter ended June 30, 2016.
DPRX: 12.57 (-0.13)
Dipexium Pharmaceuticals to Hold Second Quarter 2016 Financial Results Conference Call on Thursday, August 4, 2016, at 8:30 a.m. ET
PR Newswire - Thu Jul 28, 6:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) will release its financial results for the quarter ended June 30, 2016, on Thursday, August 4, 2016 at 7:00 a.m. ET. The announcement will be followed by a conference call at 8:30 a.m. ET during which Dipexium management will discuss these results, recent developments and answer questions.
DPRX: 12.57 (-0.13)
Dipexium Pharmaceuticals' Locilex® Microbiology Data Presented at ASM Microbe 2016 Conference
PR Newswire - Mon Jun 20, 3:01PM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), and research collaborator, R. M. Alden Research Laboratory, announced that data from two new Locilex® microbiology studies were presented at the American Society for Microbiology's Microbe conference in Boston, Massachusetts, June 16-20, 2016.
DPRX: 12.57 (-0.13)
Dipexium Announces Completion of Enrollment Objective in OneStep-1 Pivotal Phase 3 Clinical Trial
PR Newswire Europe - Mon May 16, 7:01AM CDT
Both Pivotal Phase 3 Clinical Trials Are Now Completed
DPRX: 12.57 (-0.13)
Dipexium Pharmaceuticals Announces Completion of Enrollment Objective in OneStep-2 Pivotal Phase 3 Clinical Trial and First Quarter 2016 Financial Results
PR Newswire - Thu May 12, 6:00AM CDT
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today announced that it has completed the patient enrollment objective in the OneStep-2 pivotal Phase 3 clinical trial in accordance with the requirements set forth in the OneStep-2 clinical trial protocol. The Company also announced that the OneStep-1 pivotal Phase 3 clinical trial has passed the 98% enrollment mark and is expected to reach the 180 patient enrollment objective imminently. OneStep-1 and OneStep-2 are identical, pivotal Phase 3 clinical trials conducted under a Special Protocol Assessment (SPA) agreement between the U.S. Food and Drug Administration (FDA) and Dipexium for evaluation of Locilex® for the treatment of patients with mild infections of diabetic foot ulcers (Mild DFI).
DPRX: 12.57 (-0.13)
Dipexium Pharmaceuticals to Hold First Quarter 2016 Financial Results Conference Call on Thursday, May 12, 2016, at 8:30 a.m. ET
PR Newswire - Mon May 09, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) will release its financial results for the quarter ended March 31, 2016, on Thursday, May 12, 2016 at 7:00 a.m. ET. The announcement will be followed by a conference call at 8:30 a.m. ET during which Dipexium management will discuss these results, recent developments and answer questions.
DPRX: 12.57 (-0.13)
Dipexium Pharmaceuticals (DPRX) Jumps: Stock Rises 7.5%
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 7:40AM CDT
Dipexium Pharmaceuticals, Inc. (DPRX) saw its shares rise above 7% in the last trading session.
DPRX: 12.57 (-0.13)
Will Dipexium Pharmaceuticals (DPRX) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 7:03AM CDT
As of late, it has definitely been a great time to be an investor in Dipexium Pharmaceuticals Inc (DPRX)
DPRX: 12.57 (-0.13)
Why You Shouldn't Bet Against Dipexium Pharmaceuticals (DPRX) Stock
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 7:52AM CDT
Dipexium Pharmaceuticals (DPRX) looks like an interesting choice for investors, as it is seeing solid estimate revisions and belongs to a great industry
DPRX: 12.57 (-0.13)
Dipexium Pharmaceuticals Announces Issuance of Locilex® Patent in Japan
PR Newswire - Mon Mar 28, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antimicrobial peptide, today announced that the government of Japan has issued a Locilex patent. The patent claims are directed to a novel formulation of Locilex, an antimicrobial peptide formulated as a topical cream. The issued patent has an expiry date in June 2033.
DPRX: 12.57 (-0.13)
Dipexium Pharmaceuticals Reports 2015 Financial Results
PR Newswire - Wed Mar 23, 6:00AM CDT
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antimicrobial peptide, today announced operational and financial results for the year ended December 31, 2015.
DPRX: 12.57 (-0.13)
Dipexium Progresses on Phase III Diabetic Foot Ulcer Studies
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 2:50PM CST
Dipexium (DPRX) attains 75% enrollment milestone in two phase III studies on Locilex for the treatment of patients with mild infections of diabetic foot ulcers.
DPRX: 12.57 (-0.13), OSIR: 5.09 (+0.08), LGND: 106.88 (+3.57), ANIK: 47.45 (+0.21)
Dipexium Pharmaceuticals Reaches 75% Enrollment Milestone in Pivotal Phase 3 Clinical Trials
PR Newswire - Thu Feb 04, 7:00AM CST
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today announced its OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials have reached the 75% enrollment milestone, in the aggregate, with each study having enrolled nearly the same number of patients. OneStep-1 and OneStep-2 are identical, pivotal Phase 3 clinical trials (180 patients per clinical trial) being conducted under a Special Protocol Assessment (SPA) agreement between the U.S. Food and Drug Administration and Dipexium for evaluation of Locilex® for the treatment of patients with mild infections of diabetic foot ulcers.
DPRX: 12.57 (-0.13)
Dipexium Pharmaceuticals Announces Issuance of Locilex® Patents in Australia and New Zealand
PR Newswire - Mon Feb 01, 7:00AM CST
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today announced that the governments of Australia and New Zealand have issued new Locilex patents. The patents' claims are directed to a novel formulation of Locilex, an antibiotic peptide formulated as a topical cream, and the use of Locilex as a method of treating skin or wound infections. Both issued patents have expiry dates in June 2033.
DPRX: 12.57 (-0.13)
Dipexium Pharmaceuticals (DPRX) in Focus: Stock Gains 8.5%
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 7:45AM CDT
Dipexium Pharmaceuticals, Inc. (DPRX) was a big mover last session, as the company saw its shares rise over 8% on the day.
BSTC: 37.35 (+0.76), DPRX: 12.57 (-0.13)
Dipexium Pharmaceuticals Announces Participation in September Investor Conferences
PR Newswire - Wed Aug 24, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today announced plans to participate in two September investor conferences:
DPRX: 12.57 (-0.13)
Dipexium Pharmaceuticals Reports Second Quarter 2016 Financial Results
PR Newswire - Thu Aug 04, 6:00AM CDT
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today reported financial results for the quarter ended June 30, 2016.
DPRX: 12.57 (-0.13)
Dipexium Pharmaceuticals to Hold Second Quarter 2016 Financial Results Conference Call on Thursday, August 4, 2016, at 8:30 a.m. ET
PR Newswire - Thu Jul 28, 6:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) will release its financial results for the quarter ended June 30, 2016, on Thursday, August 4, 2016 at 7:00 a.m. ET. The announcement will be followed by a conference call at 8:30 a.m. ET during which Dipexium management will discuss these results, recent developments and answer questions.
DPRX: 12.57 (-0.13)
Dipexium Pharmaceuticals' Locilex® Microbiology Data Presented at ASM Microbe 2016 Conference
PR Newswire - Mon Jun 20, 3:01PM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), and research collaborator, R. M. Alden Research Laboratory, announced that data from two new Locilex® microbiology studies were presented at the American Society for Microbiology's Microbe conference in Boston, Massachusetts, June 16-20, 2016.
DPRX: 12.57 (-0.13)
Dipexium Announces Completion of Enrollment Objective in OneStep-1 Pivotal Phase 3 Clinical Trial
PR Newswire Europe - Mon May 16, 7:01AM CDT
Both Pivotal Phase 3 Clinical Trials Are Now Completed
DPRX: 12.57 (-0.13)
Dipexium Pharmaceuticals Announces Completion of Enrollment Objective in OneStep-2 Pivotal Phase 3 Clinical Trial and First Quarter 2016 Financial Results
PR Newswire - Thu May 12, 6:00AM CDT
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today announced that it has completed the patient enrollment objective in the OneStep-2 pivotal Phase 3 clinical trial in accordance with the requirements set forth in the OneStep-2 clinical trial protocol. The Company also announced that the OneStep-1 pivotal Phase 3 clinical trial has passed the 98% enrollment mark and is expected to reach the 180 patient enrollment objective imminently. OneStep-1 and OneStep-2 are identical, pivotal Phase 3 clinical trials conducted under a Special Protocol Assessment (SPA) agreement between the U.S. Food and Drug Administration (FDA) and Dipexium for evaluation of Locilex® for the treatment of patients with mild infections of diabetic foot ulcers (Mild DFI).
DPRX: 12.57 (-0.13)
Dipexium Pharmaceuticals to Hold First Quarter 2016 Financial Results Conference Call on Thursday, May 12, 2016, at 8:30 a.m. ET
PR Newswire - Mon May 09, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) will release its financial results for the quarter ended March 31, 2016, on Thursday, May 12, 2016 at 7:00 a.m. ET. The announcement will be followed by a conference call at 8:30 a.m. ET during which Dipexium management will discuss these results, recent developments and answer questions.
DPRX: 12.57 (-0.13)
Dipexium Pharmaceuticals (DPRX) Jumps: Stock Rises 7.5%
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 7:40AM CDT
Dipexium Pharmaceuticals, Inc. (DPRX) saw its shares rise above 7% in the last trading session.
DPRX: 12.57 (-0.13)
Will Dipexium Pharmaceuticals (DPRX) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 7:03AM CDT
As of late, it has definitely been a great time to be an investor in Dipexium Pharmaceuticals Inc (DPRX)
DPRX: 12.57 (-0.13)
Why You Shouldn't Bet Against Dipexium Pharmaceuticals (DPRX) Stock
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 7:52AM CDT
Dipexium Pharmaceuticals (DPRX) looks like an interesting choice for investors, as it is seeing solid estimate revisions and belongs to a great industry
DPRX: 12.57 (-0.13)
Dipexium Pharmaceuticals Announces Issuance of Locilex® Patent in Japan
PR Newswire - Mon Mar 28, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antimicrobial peptide, today announced that the government of Japan has issued a Locilex patent. The patent claims are directed to a novel formulation of Locilex, an antimicrobial peptide formulated as a topical cream. The issued patent has an expiry date in June 2033.
DPRX: 12.57 (-0.13)
Dipexium Pharmaceuticals Reports 2015 Financial Results
PR Newswire - Wed Mar 23, 6:00AM CDT
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antimicrobial peptide, today announced operational and financial results for the year ended December 31, 2015.
DPRX: 12.57 (-0.13)
Dipexium Progresses on Phase III Diabetic Foot Ulcer Studies
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 2:50PM CST
Dipexium (DPRX) attains 75% enrollment milestone in two phase III studies on Locilex for the treatment of patients with mild infections of diabetic foot ulcers.
DPRX: 12.57 (-0.13), OSIR: 5.09 (+0.08), LGND: 106.88 (+3.57), ANIK: 47.45 (+0.21)
Dipexium Pharmaceuticals Reaches 75% Enrollment Milestone in Pivotal Phase 3 Clinical Trials
PR Newswire - Thu Feb 04, 7:00AM CST
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today announced its OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials have reached the 75% enrollment milestone, in the aggregate, with each study having enrolled nearly the same number of patients. OneStep-1 and OneStep-2 are identical, pivotal Phase 3 clinical trials (180 patients per clinical trial) being conducted under a Special Protocol Assessment (SPA) agreement between the U.S. Food and Drug Administration and Dipexium for evaluation of Locilex® for the treatment of patients with mild infections of diabetic foot ulcers.
DPRX: 12.57 (-0.13)
Dipexium Pharmaceuticals Announces Issuance of Locilex® Patents in Australia and New Zealand
PR Newswire - Mon Feb 01, 7:00AM CST
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today announced that the governments of Australia and New Zealand have issued new Locilex patents. The patents' claims are directed to a novel formulation of Locilex, an antibiotic peptide formulated as a topical cream, and the use of Locilex as a method of treating skin or wound infections. Both issued patents have expiry dates in June 2033.
DPRX: 12.57 (-0.13)
